Merck & Co called off a Phase III trial of its promising cancer drug Xevinapant after an independent panel concluded it is unlikely to meet its goals
Merck shares drop 10% as pharma giant scraps trial of promising cancer drug
Read Next
- Speculator Bets led by SOFR 3-Months & 10-Year Bonds :: InvestMacro
- Speculator Bets led by S&P500 & Russell-2000 :: InvestMacro
- Men who grew up with temperamental and immature fathers usually display these 7 behaviors later in life
- People who become less intelligent as they get older usually display these 7 behaviors, according to psychology
- How macroeconomic indicators performed in November 2024?, ET BFSI
- IFC invests $75 mn in NDR InvIT’s sustainability-linked bonds, ET BFSI
- 8 signs you have a healthy relationship with your parents (even if it doesn’t always feel like it)
